Prosecution Insights
Last updated: October 08, 2026

Nixon Peabody LLP

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

358 pending office actions • 138 clients • 332 examiners • 153 art units • 15 of 358 (4%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Nixon Peabody LLP handles 21745 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 94.64 percent. On average, the firm navigates 4.08 office actions per allowance to secure these grants. Currently, there are 266 pending office actions.

The resolved allowance rate of 94.64 percent is notable for the Biotechnology & Pharmaceuticals sector, where prosecution can be complex. The average of 4.08 office actions per allowance reflects the intensive examination process typical for the 21745 career applications managed by the firm. Practitioners can interpret the 94.64 percent allowance rate as a sign of high proficiency in securing patent rights despite the average office actions required. The 266 pending office actions indicate a substantial and active workload. With its career history, the firm possesses deep data and experience to guide its strategy in the Biotechnology & Pharmaceuticals field, ensuring that success is maintained through diligent examiner interaction.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=21745 apps, methodology: how we score firms)

85.1%
Allowance Rate
n=21745
+0.59σ
Allowance Rate (norm)
n=21745
3.6
OAs to Allowance
n=13411
+0.06σ
OAs to Allow (norm)
n=13411
1106 days
Time to Allowance
n=13411
+7.9pp
Interview Lift
n=21745
31.1%
RCE Rate
n=21745
2.5%
Appeal Rate
n=21745

Rejection Performance (% of received rejections ultimately overcome)

76.6%
§101 Overcome
n=1820
80.9%
§102 Overcome
n=5277
81.8%
§103 Overcome
n=8855
81.9%
§112 Overcome
n=5608

Specialization & Scale

G06F, H10D, A61K
Top CPC Subclasses
12%
Top-3 CPC Share
n=21745
73
Practitioners
n=21745
297.9
Apps / Practitioner
n=21745

Portfolio Summary

358
Total Pending OAs
229
Non-Final OAs
116
Final Rejections
13
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 73 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

41
Overdue
2
Due this week
18
Due this month
6
Due in next 60 days
6
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 73 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (41)Due ≤ 7 days (2)Due ≤ 30 days (18)Due ≤ 60 days (6)Due later (6)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

191
Hard (53%)
137
Medium (38%)
29
Easy (8%)
1
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only11 (3%)
§101 + other50 (14%)
§103 only92 (26%)
§102 only16 (4%)
§112 only22 (6%)
Double-patenting only7 (2%)
Double-patenting + other29 (8%)
Multi-statute (no §101)130 (36%)
No statute on record1 (0%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

123
Life Sciences
34% of docket
20
Information Tech
6% of docket
10
Communications
3% of docket
19
Semiconductors
5% of docket
87
Mechanical / Eng
24% of docket
99
Business / Other
28% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

3,580 h
Manual time on pending OAs
716 h
Time saved (low, 20%)
1,253 h
Time saved (mid, 35%)
31.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AYAD, TAMIR 3 42.3% +47.9%
VAZQUEZ COLON, MARIA E 2 73.3% +13.9%
RICCI, CRAIG D 2 53.6% +52.7%
DUCHENEAUX, FRANK D 2 45.1% -14.3%
KOMATSU, LI N 2 59.6% +70.8%
WAN, DEMING 2 76.4% +42.4%
PHAN, DOAN THI-THUC 2 42.7% +47.9%
FERNANDEZ, SUSAN EMILY 2 52.3% +60.9%
WILDER, CYNTHIA B 2 71.0% +26.6%
WIEGAND, TYLER J 2 74.5% +13.4%

Hard Cases (191)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17752300 DISPOSABLE INFANT INCUBATOR AND DISPOSABLE CONTAINED MICROENVIRONMENT FOR STATIONARY OR TRANSPORT CASES COX, THADDEUS B 78d overdue
18687788 BIOFEEDBACK COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA NG, JONATHAN K 77d overdue
18112007 LINERLESS LABEL AND METHOD FOR PREPARING A LABEL WALSHON, SCOTT R 71d overdue
18657582 SYSTEM AND METHOD FOR IMPROVING HUMAN-CENTRIC PROCESSES WAESCO, JOSEPH M 66d overdue
17797633 METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS O'NEILL, MARISOL ANN 60d overdue
18387108 RELEASE LINER AND A LABEL LAMINATE WALSHON, SCOTT R 51d overdue
18277934 CONTAINER MULTILAYERED BODY, CONTAINER, MEDICAL CONTAINER, AND DRUG-CONTAINING MEDICAL CONTAINER ARBLE, JESSICA R 51d overdue
18424292 COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA PAULUS, ERIN VIRGINIA 45d overdue

Interview Candidates (19)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17565834 METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS FERNANDEZ, SUSAN EMILY 112d overdue
17879405 CAMERA BALL TURRET HAVING HIGH BANDWIDTH DATA TRANSMISSION TO EXTERNAL IMAGE PROCESSOR VAZQUEZ COLON, MARIA E 38d overdue
19261893 INSPECTION AND IDENTIFICATION SYSTEM AND METHOD VAZQUEZ COLON, MARIA E —
19171111 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF RICCI, CRAIG D —
19089551 INSECT NEUROPEPTIDES 1 KOMATSU, LI N —
18925577 COMPLEX WAVELENGTH UV LED CONVEYOR SYSTEM WAN, DEMING —
18923866 MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGEL, A METHOD FOR TREATING A SUBJECT IN NEED OF TREATMENT OF BODY WITH IMPLANTABLE MATERIAL AND A METHOD FOR MANUFACTURING THE MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGEL PHAN, DOAN THI-THUC —
18855498 METHODS OF TREATING AND DIAGNOSING FATTY LIVER DISEASE FERNANDEZ, SUSAN EMILY —

Client Portfolio (138 clients)

View all 138 →

Top Art Units

Art UnitApps
379112
378510
16336
16326
16585
16315
36194
17884
17264
16724

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19386469 A PROTECTIVE HEADBAND Huvudsäker Idrott I Sverige AB HOEY, ALISSA L 3732 §102§112 Non-Final OA — Pending Nov 12, 2025
19168970 SYSTEMS, APPARATUSES, AND METHODS FOR DELIVERING EXPLOSIVE COMPOSITIONS INTO BOREHOLES Orica International Pte. Ltd. BERGIN, JAMES S 3641 §112 Non-Final OA — Pending Sep 25, 2025
19324971 IMAGE COMPENSATION METHOD AND APPARATUS, COMPUTER DEVICE, COMPUTER-READABLE STORAGE MEDIUM, AND COMPUTER PROGRAM PRODUCT Glenfly Tech Co., Ltd. TZENG, FRED 2625 §103 Non-Final OA — Pending Sep 10, 2025
19149775 POLYAXIAL SCREW ASSEMBLY AND ORTHOPEDIC COMPONENT Limacorporate S.p.A. LAWSON, MATTHEW JAMES 3619 §103§112 Final Rejection — Pending Jul 21, 2025
19267597 DYNAMIC IMPLEMENTATION AND MANAGEMENT OF HASH-BASED CONSENT AND PERMISSIONING PROTOCOLS The Toronto-Dominion Bank SHOLEMAN, ABU S §103§112Other Non-Final OA — Pending Jul 13, 2025
19261423 METHODS AND SYSTEMS FOR USER DATA MANAGEMENT I Own My Data LLC DINH, KHANH Q §102§103 Non-Final OA — Pending Jul 07, 2025
19261893 INSPECTION AND IDENTIFICATION SYSTEM AND METHOD Bwi Acquisition, LLC VAZQUEZ COLON, MARIA E DP Non-Final OA — Pending Jul 07, 2025
19232398 ON-DEMAND ACTIVATION OF MEMORY PATH DURING SLEEP OR ACTIVE MODES Ambiq Micro, Inc. CHERY, MARDOCHEE DP Non-Final OA — Pending Jun 09, 2025
19231203 SYSTEM AND METHOD FOR HIGHLY SECURE REMOTE CONNECTION PATHWAYS BETWEEN ENDPOINT DEVICES AND CLOUD DESKTOPS Workspot, Inc. NANO, SARGON N §101§103§112 Non-Final OA — Pending Jun 06, 2025
19216123 ADJUSTING FEEDBACK SYSTEM FOR AN INTRAORAL DEVICE ResMed MOK, ANDREW JUN-WAI 3786 §102§103§112 Non-Final OA — Pending May 22, 2025
19198069 DYNAMIC MANAGEMENT AND IMPLEMENTATION OF CONSENT AND PERMISSIONING PROTOCOLS USING CONTAINER-BASED APPLICATIONS The Toronto-Dominion Bank SIDDIQI, MOHAMMAD A §103Other Non-Final OA — Pending May 04, 2025
19193163 MULTI-ENTITY PLATFORM USING UNIFORM LABELING OF DATA PRODUCTS AND SERVICES Vendex Solutions, Inc. CHEIN, ALLEN C 3627 §101§103 Final Rejection — Pending Apr 29, 2025
19123191 METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS Cedars-Sinai Medical Center NGUYEN, HIEP VAN 3686 §101§103§112 Non-Final OA — Pending Apr 22, 2025
19179593 METHOD AND SYSTEM RECOVERY FROM UNEXPECTED MEMORY CORRUPTION ON A SYSTEM ON CHIP Ambiq Micro, Inc. GRIJALVA LOBOS, BORIS D §102§103§112 Non-Final OA — Pending Apr 15, 2025
19177602 SECURE DEPLOYMENT OF DE-RISKED CONFIDENTIAL DATA WITHIN A DISTRIBUTED COMPUTING ENVIRONMENT The Toronto-Dominion Bank LITTLE, VANCE M §102§103DP Non-Final OA — Pending Apr 13, 2025
19171111 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF Trustees Of Boston University RICCI, CRAIG D 1611 §102 Final Rejection — Pending Apr 04, 2025
19090002 INSECT NEUROPEPTIDES 3 Solasta Bio Limited FISCHER, JOSEPH 1658 §101§103§112 Final Rejection — Pending Mar 25, 2025
19089531 LINERLESS LABEL UPM RAFLATAC OY DUCHENEAUX, FRANK D 1788 §112 Non-Final OA — Pending Mar 25, 2025
19089551 INSECT NEUROPEPTIDES 1 Solasta Bio Limited KOMATSU, LI N 1658 §103 Final Rejection — Pending Mar 25, 2025
19080158 TWO-PHASE CLOSED THERMOSYPHON WITH INTERNAL ADIABATIC SECTION FOR EFFICIENT ULTRA-LONG-DISTANCE HEAT EXCHANGE Northwest Institute Of Eco-Environment And Resources, Chinese Academy Of Sciences NIEVES, NELSON J §112 Non-Final OA — Pending Mar 14, 2025
19078477 METHOD AND SYSTEM FOR MEASURING PUPILLARY LIGHT REFLEX WITH A MOBILE PHONE Biotrillion, Inc. BROOME, SHARRIEF I §101§102§112 Non-Final OA — Pending Mar 13, 2025
19074251 SYSTEMS AND METHODS FOR PREDICTING ADOPTION OF A THERAPY ResMed TEJANI, ANKIT D Other Non-Final OA — Pending Mar 07, 2025
19064417 METHODS AND SYSTEMS TO REPAIR CONSTRUCTED INFORMATION Quanta Computer Inc. MISIURA, BRIAN THOMAS 2175 §102§112 Non-Final OA — Pending Feb 26, 2025
19060108 METHOD FOR MANUFACTURING RECTANGULAR-BOTTOMED PACKAGING BAG, DEVICE FOR MANUFACTURING RECTANGULAR-BOTTOMED PACKAGING BAG, METHOD FOR MANUFACTURING PACKAGING BODY, AND DEVICE FOR MANUFACTURING PACKAGING BODY Hosokawa Yoko Co., Ltd. TAWFIK, SAMEH 3731 §103 Non-Final OA — Pending Feb 21, 2025
19105750 FILE ARCHIVE FOR GEOGRAPHIC RASTER DATA Ellipsis Earth Intelligence B.V. GURMU, MULUEMEBET 2163 §101§103 Non-Final OA — Pending Feb 21, 2025
19058224 METHOD FOR CARRYING OUT PATIENT REGISTRATION ON A MEDICAL VISUALIZATION SYSTEM, AND MEDICAL VISUALIZATION SYSTEM Carl Zeiss Meditec AG BASHIR, ADEEL §103 Non-Final OA — Pending Feb 20, 2025
19104141 SYSTEMS AND METHODS FOR DETERMINING A RISK FACTOR FOR A CONDITION ResMed BRUCE, FAROUK A 3797 §101§103 Final Rejection 49d AI Ready Feb 14, 2025
19103314 SEMICONDUCTOR DEVICE AND METHOD FOR DRIVING THE SEMICONDUCTOR DEVICE Semiconductor Energy Laboratory Co., Ltd. BERMUDEZ LOZADA, ALFREDO §102 Non-Final OA — Pending Feb 12, 2025
19045444 SYSTEMS AND METHODS FOR UNIFORM USAGE RIGHTS MANAGEMENT Vendex Solutions, Inc. ALI, JAHED 3699 §101 Final Rejection 15d overdue Pending Feb 04, 2025
19040020 CLOSURE WITH THREADING Closure Systems International Inc. ISLAM, SANJIDUL 3736 §103 Final Rejection 6d Pending Jan 29, 2025
19038381 LIGHTING DEVICES FOR CEILING GRIDS Dado Lighting, LLC DIAZ, JOSE DP Non-Final OA — Pending Jan 27, 2025
19035397 A METHOD FOR INHIBITING BINDING OR CROSS-LINKING TO VASCULAR ENDOTHELIAL CELLS Royal College Of Surgeons In Ireland SPENCE, JENNIFER SUZANNE 1633 §102 Non-Final OA — Pending Jan 23, 2025
19028938 RELEASABLE FAN MODULE ASSEMBLY Quanta Computer Inc. PEKARSKAYA, LILYA 3746 §103 Final Rejection — Pending Jan 17, 2025
19025127 CRICOTHYROTOMY MEDICAL TRAINING DEVICE AND METHOD 26 Delta 1 LLC MUSA, BUSHIRA 3715 §102§103 Non-Final OA — Pending Jan 16, 2025
19016533 NOISE REDUCTION APPARATUS FOR CONTROL ROD POSITION INDICATOR Korea Hydro & Nuclear Power Co., Ltd. DAVIS, SHARON M §103§112 Non-Final OA — Pending Jan 10, 2025
18879472 SYSTEM AND METHOD FOR DATA RECONCILIATION FOR TRANSFER TO CLOUD STORAGE ResMed SANA, MOHAMMAD AZAM 2166 §101§103§112 Non-Final OA — Pending Dec 27, 2024
19002198 SERVO-CONTROLLED MACHINE LINE BELVAC PRODUCTION MACHINERY, INC. HARP, WILLIAM RAY §103DP Non-Final OA — Pending Dec 26, 2024
18989566 INTEGRATION OF MICRODEVICES INTO SYSTEM SUBSTRATE Vuereal Inc. RAABE, CHRISTOPHER M §102§112 Non-Final OA — Pending Dec 20, 2024
18990784 GENERATING ADAPTIVE TEXTUAL EXPLANATIONS OF OUTPUT PREDICTED BY TRAINED ARTIFICIAL-INTELLIGENCE PROCESSES The Toronto-Dominion Bank SIRJANI, FARIBA DP Non-Final OA — Pending Dec 20, 2024
18989638 POWER STORAGE SYSTEM AND POWER STORAGE DEVICE Semiconductor Energy Laboratory Co., Ltd. CHEN, XUXING 2176 §103§112 Non-Final OA — Pending Dec 20, 2024
18977418 FUNCTIONAL PANEL, DEVICE, AND DATA PROCESSOR Semiconductor Energy Laboratory Co., Ltd. TOLIN, MICHAEL A §102 Non-Final OA — Pending Dec 11, 2024
18872137 METHOD FOR PRODUCING CRYSTALLINE RESIN SHEET Kotsugisya Co., Ltd. MACHNESS, ARIELLA 1743 §103 Non-Final OA — Pending Dec 05, 2024
18870276 METHOD AND SYSTEM FOR INGESTING AND EXECUTING ELECTRONIC CONTENT PROVIDING PERFORMANCE DATA AND ENABLING DYNAMIC AND INTELLIGENT AUGMENTATION Augmentir Inc. VU, KIEU D §101§102§103 Non-Final OA — Pending Nov 27, 2024
18867249 DATA READING METHOD AND APPARATUS, AND ELECTRONIC DEVICE Cong Lu CHOI, CHARLES J 2175 §103 Non-Final OA — Pending Nov 19, 2024
18952127 Modular Furniture Assembly Cushy Holdings, Inc. WUJCIAK, ALFRED J 3636 §112DP Non-Final OA — Pending Nov 19, 2024
18945685 PRIORITIZATION OF MULTIPLE OBJECTS IN AN ASSISTANCE FUNCTIONALITY FOR A SURGICAL MICROSCOPY SYSTEM Carl Zeiss Meditec AG FANG, MICHAEL YIMING §102§103 Non-Final OA — Pending Nov 13, 2024
18864459 LINERLESS LABEL UPM RAFLATAC OY DUCHENEAUX, FRANK D 1788 §103§112 Non-Final OA — Pending Nov 08, 2024
18862311 RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS Cedars-Sinai Medical Center GEMBEH, SHIRLEY V §103 Non-Final OA — Pending Nov 01, 2024
18935258 Deployment Of Quasi-Planar Shock Wave Generators In Association With Seismic Exploration Orica International Pte. Ltd. ABULABAN, ABDALLAH 3645 §103 Non-Final OA — Pending Nov 01, 2024
18934780 SECURE RESOLUTION OF EMAIL-BASED QUERIES INVOLVING CONFIDENTIAL THIRD-PARTY DATA The Toronto-Dominion Bank LI, MENG §101§103 Final Rejection — Pending Nov 01, 2024

View all 358 →

Managing Nixon Peabody LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Nixon Peabody LLP's patent allowance rate?

85.1% of resolved applications prosecuted by Nixon Peabody LLP were allowed, across 21,745 applications in USPTO records.

How many office actions does Nixon Peabody LLP average before allowance?

3.61 office actions per allowed application on average.

How many pending office actions does Nixon Peabody LLP have?

358 pending office actions as of October 2026, for 138 clients, before 332 examiners in 153 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month